| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 27.48 | 13.5% | 9.1% |
| Total Income | 27.48 | 13.5% | 9.1% |
| Expenditure | 54.87 | 16.4% | 28.4% |
| PBT | -34.40 | 29.7% | 45.9% |
| Net Profit | -33.35 | 33.2% | 40.9% |
| OPM | -99.65% | 30.04pp | |
| NPM | — | ||
| EPS | -0.69 | 34.3% | 25.4% |
UroGen Pharma Announces Q3 2025 Results
04 May 2026 · 4 May, 7:45 am
Summary
UroGen Pharma Ltd. announced its financial results for the quarter ended September 30, 2025, as detailed in the attached press release.
Informational and educational content only. Not investment advice.